Pre-registration efficacy studies of a novel marker vaccine against classical swine fever on target animals

被引:0
|
作者
Levai Reka [1 ]
Barna Timea [1 ]
Fabian Katalin [1 ]
Sandra Blome [2 ]
Belak Katinka [3 ]
Balint Adam [4 ]
Frank Koenen [5 ]
Kulcsar Gabor [1 ]
Farsang Attila [1 ,6 ]
机构
[1] Nemzeti Elelmiszerlanc Biztonsagi, Allatgyogyaszati Termekek, Szallas Utca 8, H-1107 Budapest, Hungary
[2] Friedrich Loeffler Inst, Insel Riems, Germany
[3] Natl Vet Inst, Uppsala, Sweden
[4] Nemzeti Elelmiszerlanc Biztonsagi, Allategeszsegugyi Diagnosztikai Igazgatosag, Budapest, Hungary
[5] Vet & Agrochem Res Ctr, Uccle, Belgium
[6] Ceva Phylaxia Zrt, Budapest, Hungary
关键词
CANDIDATE CP7-E2ALF; VIRUS; DIFFERENTIATION; PESTIVIRUSES; NETHERLANDS; INFECTION; PIGS;
D O I
暂无
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Background: Classical swine fever (CSF) or hog cholera is a highly contagious and devastating disease of Suidae caused by an enveloped single-stranded RNA virus (CSFV) of the family Flaviviridae, genus Pestivirus. CSF has vast economic and trade significance all over the world, and it has the massive potential to spread rapidly from country to country. This is the reason why the World Organisation for Animal Health has listed CSF as a Notifiable Disease and it is also considered a transboundary animal disease. Objective: The objective of the present studies was to determine the efficacy of a single dose of a newly developed marker vaccine candidate against CSF, administered intramuscularly or orally in 6-week-old domestic piglets with and without maternally derived antibodies (MDAs) against Pestiviruses, to provide protection against a challenge with the highly virulent CSFV strain Koslov 14 days post vaccination. Materials and Methods: In both experiments two test groups were formed with 15 animals each, one group for intramuscular (im.), while another one for oral (p.o.) immunisation. The control groups contained 10 animals as unvaccinated controls, respectively. All piglets were oronasally challenged with the highly virulent CSF virus (CSFV) strain Koslov 14 days post-vaccination. Results and Discussion: The vaccine candidate when administered im. provided complete protection in MDA- animals, while p.o. administration triggered only partial protection. Furthermore, we found that the presence of the MDAs had negative effect on the efficacy of the vaccine candidate. However, this was greatly influenced by the route of administration. Based on our observations, im. administration is recommended to achieve better immune response during the CSF control programs. The vaccine candidate met the criteria of Ph. Eur Monograph 0065, Swine-fever vaccine (live, prepared in cell cultures), classical 7th Edition. Fulfilling these validity criteria is a key step in the registration procedure for a vaccine candidate.
引用
收藏
页码:227 / 243
页数:17
相关论文
共 50 条
  • [1] Pre-registration efficacy study of a novel marker vaccine against classical swine fever on maternally derived antibody positive (MDA plus ) target animals
    Farsang, A.
    Levai, R.
    Barna, T.
    Fabian, K.
    Blome, S.
    Belak, K.
    Balint, A.
    Koenen, F.
    Kulcsar, G.
    BIOLOGICALS, 2017, 45 : 85 - 92
  • [2] Pre-registration efficacy study of a novel marker vaccine against classical swine fever on Maternally Derived Antibody negative (MDA-) target animals
    Levai, R.
    Barna, T.
    Fabian, K.
    Blome, S.
    Belak, K.
    Balint, A.
    Koenen, F.
    Kulcsar, G.
    Farsang, A.
    BIOLOGICALS, 2015, 43 (02) : 92 - 99
  • [3] Novel marker vaccines against classical swine fever
    Beer, Martin
    Reimann, Ilona
    Hoffmann, Bernd
    Depner, Klaus
    VACCINE, 2007, 25 (30) : 5665 - 5670
  • [4] Efficacy of a Commercial Swine Fever Vaccine against a virulent Thailand isolate of Classical Swine Fever Virus
    Ming, Yong
    Allison, Jim
    Lehrbach, Phil
    Navasakuljinda, Wichian
    Poolperm, Pariwat
    HEALTHY PIG FOR HEALTHY LIFE, PROCEEDINGS OF THE 5TH ASIAN PIG VETERINARY SOCIETY CONGRESS, 2011, 2011, : P67 - P67
  • [5] Safety, efficacy, and DIVA feasibility on a novel live attenuated classical swine fever marker vaccine candidate
    Tong, Chao
    Liu, Huanhuan
    Wang, Jiaying
    Sun, Yanyong
    Chen, Ning
    VACCINE, 2022, 40 (50) : 7219 - 7229
  • [6] The influence of maternal immunity on the efficacy of a classical swine fever vaccine against classical swine fever virus, genogroup 2.2, infection
    Suradhat, S
    Damrongwatanapokin, S
    VETERINARY MICROBIOLOGY, 2003, 92 (1-2) : 187 - 194
  • [7] Efficacy of the classical swine fever (CSF) marker vaccine Porcilis® Pesti in pregnant sows
    Ahrens, U
    Kaden, V
    Drexler, C
    Visser, N
    VETERINARY MICROBIOLOGY, 2000, 77 (1-2) : 83 - 97
  • [8] Evaluation of genetic vaccine against classical swine fever
    Markowska-Daniel, I
    Collins, RA
    Pejsak, Z
    VACCINE, 2001, 19 (17-19) : 2480 - 2484
  • [9] Development of a live attenuated antigenic marker classical swine fever vaccine
    Holinka, L. G.
    Fernandez-Sainz, I.
    O'Donnell, V.
    Prarat, M. V.
    Gladue, D. P.
    Lu, Z.
    Risatti, G. R.
    Borca, M. V.
    VIROLOGY, 2009, 384 (01) : 106 - 113
  • [10] Efficacy of chimeric Pestivirus vaccine candidates against classical swine fever: Protection and DIVA characteristics
    Eble, P. L.
    Geurts, Y.
    Quak, S.
    Moonen-Leusen, H. W.
    Blome, S.
    Hofmann, M. A.
    Koenen, F.
    Beer, M.
    Loeffen, W. L. A.
    VETERINARY MICROBIOLOGY, 2013, 162 (2-4) : 437 - 446